Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

353
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
353
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

372
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
372
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Sample Size Calculation01:19

Sample Size Calculation

5.1K
Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
5.1K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

405
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
405
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

427
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
427

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry study.

Experimental and therapeutic medicine·2026
Same author

Identifying expression and DNA methylation biomarkers for lung adenocarcinoma risk in East Asia.

Journal of the National Cancer Institute·2026
Same author

SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).

European journal of cancer (Oxford, England : 1990)·2026
Same author

Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers.

Journal of the National Cancer Institute·2025
Same author

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration.

Journal of hepatology·2025
Same journal

Invaders taking over-Mollusc faunal change in volcanic barrier lakes of the Albertine Rift biodiversity hotspot.

PloS one·2026
Same journal

AI-driven molecular diversification and ligand-based optimization of macitentan derivatives targeting VEGFR1 and endothelin signaling pathways.

PloS one·2026
Same journal

Performance patterns and records in the world aquatics masters championships: Where do the most frequently represented nations among the top-ten masters swimmers come from?

PloS one·2026
Same journal

Modeling diurnal Temperature-Rainfall relationships under multicollinearity using PLS-SEM: A case study of Ghana.

PloS one·2026
Same journal

Organizational culture, social capital, and emergency capacity in primary healthcare institutions: A cross-sectional structural equation modeling study comparing ordinary and older communities.

PloS one·2026
Same journal

Impact of kidney function on the metabolome in the general population.

PloS one·2026
See all related articles

Related Experiment Video

Updated: Apr 22, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

Sample size determination for individual bioequivalence inference.

Chieh Chiang1, Chin-Fu Hsiao1, Jen-Pei Liu2

  • 1Division of Biometry, Department of Agronomy, National Taiwan University, Taipei, Taiwan; Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.

Plos One
|October 14, 2014
PubMed
Summary
This summary is machine-generated.

This study provides a method for determining sample sizes for individual bioequivalence (IBE) testing of generic drugs. The new approach uses asymptotic power derived from the upper confidence bound of a linearized criterion, addressing a gap in current FDA guidance.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K
Modeling the Size Spectrum for Macroinvertebrates and Fishes in Stream Ecosystems
07:41

Modeling the Size Spectrum for Macroinvertebrates and Fishes in Stream Ecosystems

Published on: July 30, 2019

7.1K

Related Experiment Videos

Last Updated: Apr 22, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.1K
Modeling the Size Spectrum for Macroinvertebrates and Fishes in Stream Ecosystems
07:41

Modeling the Size Spectrum for Macroinvertebrates and Fishes in Stream Ecosystems

Published on: July 30, 2019

7.1K

Area of Science:

  • Biostatistics
  • Pharmacokinetics
  • Drug Development

Background:

  • Individual bioequivalence (IBE) assessment is crucial for generic drug approval.
  • Current FDA guidance for IBE uses an aggregate criterion based on second moments, but sample size determination is challenging due to power function complexity.

Purpose of the Study:

  • To derive the asymptotic distribution of the upper confidence bound for the linearized IBE criterion.
  • To enable sample size determination for IBE evaluations under specific crossover designs.

Main Methods:

  • Utilized a two-sequence, four-period replicated crossover design.
  • Derived the asymptotic distribution of the upper confidence bound of the linearized criterion.
  • Calculated asymptotic power for sample size determination.

Main Results:

  • The asymptotic distribution of the upper confidence bound was successfully derived.
  • Asymptotic power was established, facilitating sample size calculations for IBE.
  • Numerical studies confirmed the derived methods.

Conclusions:

  • The study provides a statistically sound method for sample size determination in IBE evaluations.
  • This approach supports practical applications of IBE testing based on the FDA's aggregate criterion.